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Abstract—Acute hemorrhagic lung injury occurs in humans with anti-GBM antibody
(Goodpasture's syndrome), however, the mechanism of this injury is still largely
unknown. To date, treatment has been confined to steroids and plasmaphoresis.
Infusion of anti-GBM antibody into rats caused lung injury with intra-alveolar
hemorrhage and intrapulmonary accumulation of neutrophils. Lung injury was
dependent on the presence of neutrophils and complement and required both
TNFa and IL-1. Experiments employing blocking antibodies to adhesion molecules
demonstrated requirements for the Q1 integrin VLA-4, #2 integrins LFA-1 and Mac-1,
and L-selectin. The endothelial cell adhesion molecules, E-selectin and ICAM-1, were
also required for the full development of lung injury. Inhibition of TNFa or IL-1
or adhesion molecules reduced both lung injury and tissue neutrophil accumulation.
Thus, this study underscores cytokine and adhesion molecule requirements for
neutrophil mediated injury in lung and kidney caused by anti-GBM, suggesting
potential targets for the treatment of Goodpasture's syndrome in humans.
INTRODUCTION
The presence of circulating antibody to glomerular basement membrane
(anti-GBM) in humans is known to be associated with the development of both
renal glomerular and pulmonary vascular adnormalities (1-6). The clinical pat-
tern of anti-GBM-related nephritis varies from a relatively mild focal glomeru-
lonephritis with hematuria to crescentic glomerulonephritis rapidly progressing
to renal failure (7). In these patients there may also be pulmonary manifestations
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that are associated with acute, life-threatening bouts of intra-alveolar hemorrhage
and diffuse alveolar damage (Goodpasture's syndrome). It is known experimen-
tally that sheep or rabbit antibody to rat glomerular GBM reacts with both renal
and lung vascular basement membranes (2, 7, 8). The chief basement membrane
component that is reactive with anti-GBM antibody appears to be the a3 chain
of type IV collagen (9). Polyclonal IgG sheep antibodies to rat GBM, to murine
type IV collagen, and to laminin produce evidence of acute lung injury, coinci-
dent with fixation of the antibody to the pulmonary vasculature (10, 11).
In the current studies we employed a rat model to define the mechanisms
of acute lung injury following infusion of sheep anti-rat-GBM. The data demon-
strate requirements of cytokines and adhesion molecules in the development of
anti-GBM-induced lung injury. These studies delineate many similarities but also
some distinct differences with respect to mediators required for induction of
acute lung injury and development of acute renal glomerular injury. These find-
ings may provide insight into the development of new therapeutic strategies for
the treatment of humans with Goodpasture's syndrome.
METHODS
Animal Model of Anti-GBM-induced Acute Alveolitis. Sheep polyclonal IgG rich in anti-rat
GBM was prepared by immunization of sheep with rat GBM as previously described (12). Male
Long-Evans specific pathogen-free rats (300-350 g; Charles River Breeding Laboratories, Portage,
Michigan) were used for all studies. Intraperitoneal ketamine (100 mg/kg) was used for sedation
and anesthesia. For studies of lung vascular permeability, 10 mg sheep IgG anti-GBM was mixed
with 0.5 /iCi 125I-BSA and injected intravenously in a total volume of 0.5 ml. Negative control
rats received 10 mg of sheep IgG obtained from pre-immune serum. For studies of alveolar hem-
orrhage, 0.5 /*Ci of 5lCr-rat RBC was injected intravenously prior to injection of anti-GBM. The
anti-GBM preparations contained very low levels (650 fg) of endotoxin activity, as measured by
the Limulus amebocyte lysate assay (Sigma Chemical Co., St. Louis, Missouri). Rats were sacri-
ficed 6 h after injection of anti-GBM and the pulmonary circulation was flushed with 10 ml saline
by pulmonary artery injection. Changes in lung vascular permeability or alveolar hemorrhage were
assessed by comparing 125I- or 51Cr-radioactivity in lungs to counts present in 1.0 ml blood. Positive
controls received either anti-GBM alone for complement and neutrophil depletion studies, 200 pg
non-specific MOPC-21 IgG1 intravenously for protocols employing blocking monoclonal antibodies
to leukocyte and endothelial cell adhesion molecules, or 1.0 ml preimmune serum intravenously for
cytokine requirement studies.
Strategies for in vivo Blockade of Adhesion Molecules and Cytokines. The dosing schedules
for blocking of the rat /31 integrin CD49d; rat f2 integrins, CDlla, CDllb, and CD18; rat E- and
L-selectins; rat ICAM-1, and rat TNFa and IL-1 were determined on the basis of previous studies in
which these blocking agents were administered intravenously and shown to block inflammatory reac-
tions after intrapulmonary deposition of IgG immune complexes. The blocking agents are described
below.
MAb to Rat VLA-4 <CD49d). Anti-rat CD49d, clone TA-2, was a gift from Dr. Thomas
Issekutz (Dalhousie University, Halifax, Canada). This antibody is of the IgG1 subclass and is reative
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with the a4 chain (CD49d) of 01 integrin. It blocks binding of rat lymphocytes to cytokine-activated
vascular endothelial cells (13). When used, 800 fig (0.25 ml) TA-2 IgGi were infused intravenously
just prior to, and 4 h after infusion of anti-GBM. Using this protocol, a single intravenous injection of
this antibody strongly inhibits lymphocytes accumulation in delayed-type cutaneous hypersensitivity
reactions in rats (14).
MAb to Rat LFA-1 (CDIla). Anti-rat CDlla, clone WT-I, is of the IgG2a sublcass and
recognizes a leukocyte epitope of 160 to 170 kDa, but does not react with the 95 kDa j8-subunit of
LFA-1 (15). WT-1 blocks binding of rat lymphocytes to cultured endothelial cells obtained from
venules in rat lymph nodes as described elsewhere (16). When used, 200 jig intact WT-1 were
injected intravenously immediately prior to infusion of anti-GBM.
MAb to Rat Mac-1 (CDIlb). Anti-rat CD lib, clone lB6c, isof themurinelgGi subclass, and
has been previously characterized (17). It does not bind to rat lymphocytes but blocks aggregation of
PMA-activated rat neutrophils. A total of 200 /ig intact lB6c was injected intravenously immediately
prior to infusion of anti-GBM.
MAb to Rat CD18. Anti-rat CD18, clone CL26, was a gift from Dr. C. Wayne Smith (Baylor
College of Medicine, Houston, Texas). This antibody is of the murine IgGi subclass and binds to
rat neutrophils, lymphocytes, and monocytes. It reacts with a 95-kDa protein, consistent with the
0-chain of CD18 (18). Since intravenous infusion of intact IgGi CL-26 produced neutropenia (17),
F(ab'h fragments were prepared and were found not to induce neutropenia. When used, 67 /<g
F(ab')2 anti-CD 18 were injected intravenously 2, 4 and 5 h after infusion of anti-GBM.
MAb to Rat E-selectin. Anti-E-selectin, clone CL-3, was a gift from Dr. Donald C. Anderson
(Upjohn Co., Kalamazoo, Michigan). The F(ab')2 preparation rather than intact IgGi was used, since
the intact antibody neither prevents adherence of phorbol ester-stimulated rat blood neutrophils to
TNFa-treated RPAEC nor does it protect against IgG immune complex-induced acute lung injury
(19). When used, 67 /tg F(ab')2 CL-3 were injected intravenously 2, 4 and 5 h after infusion of
anti-GBM.
MAb Rat L-selectin (HRL1). Hamster mAb to rat L-selectin, clone HRL1, was generated as
previously described (20). This antibody is of the IgGi subclass and reacts with EL-4 cells trans-
fected with the cDNA for rat L-selectin but not with El-4 cells transfected with vector alone. HRL1
also blocks binding of yeast polymannon [containing the polyphosphomannon ester (PPME)] to rat
lymphocytes and blocks binding of rat endothelial cells (derived from high endothelial venules of rat
lymph nodes) to solid phase rat L-selectin-Ig affixed to the surfaces of plastic dishes. Because intact
anti-L-selectin caused neutropenia in rats, F(ab'h fragments were employed as described previously
(20). When used, 67 \i.% F(ab')2 HRL1 were injected intravenously 2, 4 and 5 h after infusion of
anti-GBM.
MAb to Rat 1CAM-1. Anti-rat ICAM-1, clone 1A29, recognizes rat ICAM-1 based on: 1) its
ability to inhibit homotypic aggregation of T-cell blasts induced by addition of phytohemagglutinin;
2) antigen precipitation analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis; 3)
by antigen distribution on frozen sections of postcapillary venules; and 4) cytokine-induced upreg-
ulation of this antigen on rat endothelial cells (21). When used in vivo for blocking activity, the
antibody was used as F(ab'h fragments since the intact antibody does not interfere with adhesion
interactions between neutrophils and the activated endothelium. When used, 67 /xg F(ab')2 IA29
were injected intravenously 2, 4 and 5 h after infusion of anti-GBM.
Polyclonal Anti-TNFa. Anti-TNFa polyclonal goat IgG antibody was raised to recombinant
murine TNF« and found to cross-react with rat TNFa (22). When used, 1.0 ml immune goat serum
was injected intravenously immediately after infusion of anti-GBM. Anti-TNFa treatment blocks
appearance of TNFa in rat bronchoalveolar fluids after intrapulmonary deposition of IgG immune
complexes (22).
Interleukin-1 Receptor Antagonist. The preparation of human recombinant IL-1 receptor
antagonist (IL-1Ra) has been previously described (23). Subcutaneous injection of IL-1Ra (2 mg/kg)
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just prior to infusion of anti-GBM, followed by intravenous injections of 1 mg/kg 2,4, and 5 h after
infusion of anti-GBM was in accord with an established protocol that provides profound IL-1 recep-
tor blockade in rats (12).
Lipopolysaccharide (LPS) Content of Monoclonal Antibodies. All MAb were evaluated for
LPS content using a Limulus amebocyte lysate assay (Sigma Chemical Co.). On the basis of the
amount used for each antibody (given intravenously), the amounts of endotoxin equivalent used
in vivo were: 6 ng for anti-VLA-4 (TA-2), 10 ng for anti-CDlla (WT1), 6.8 ng for anti-CDllb
(1B6c), 1 ng for anti-CD 18, 1.4 ng for anti-L-selectin (HRL-1), 1 pg for anti-GBM, 1.2 ng for
anti-E-selectin and 96 pg for anti-ICAM-1 (1A29). The amounts for MOPC-21, pre-immune control
serum and anti-TNFa were all less than 10 pg.
Complement Blockade and Neutrophil Depletion. Complement blockade was achieved by
the use of human recombinant sCRl (kindly provided by Dr. Una Ryan, T-Cell Sciences, Cam-
bridge, Massachusetts). Human recombinant sCR1 was injected subcutaneously (15 mg/kg) into
rats 6 h before anti-GBM. This dose has been shown to protect against complement-mediated tissue
injury (23). Neutrophil depletion was achieved by intraperitoneal injection of 1.0 ml rabbit anti-rat
neutrophil antibody (Accurate Chemical and Scientific Corp., Westburg, New York) 16 h before infu-
sion of anti-GBM. This technique reduces blood neutrophil counts by >99% (to <10 neutrophil/mm3
blood).
Tissue Extraction of MPO Content. Tissue samples were extracted by homogenization and
sonication in phosphate buffer. MPO activity in supernatants was measured by the change in optical
density (at 460 nm) resulting from decomposition of H2O2 in the presence of O-dianisidine (22).
Immunofluorescence Analysis of Lung. Lungs were inflated with optimal cutting tempera-
ture (OCT) compound. Frozen sections were acetone-fixed, washed in PBS and then incubated with
FITC-rabbit anti-sheep IgG. After incubation for 10 min at 27°C, sections were washed in PBS,
coverslips attached and examined by fluorescence microscopy.
Lung Morphology. Six hours after infusion of anti-GBM, lungs were inflated with 10%
buffered formalin and embedded in plastic. Tissue sections (1 ^m) were obtained and stained with
toluidine blue for morphologic evaluation.
Statistical Analysis. All values are expressed as mean ± SEM. Data were analyzed with a
one-way analysis (ANOVA) of variance and individual group means were then compared with a
Tukey's test. Differences were considered significant when P < 0.05. For calculations of percent
change, negative control values were subtracted from positive control and treatment group values.
RESULTS
Lung Injury Induced by Sheep IgG Anti-GBM. Intravenous infusion of
10 mg IgG anti-GBM resulted in acute lung injury as assessed by lung per-
meability, alveolar hemorrhage and lung MPO content (Figure 1). In all cases,
the differences between the two groups were statistically significant (P < 0.05),
with values from anti-GBM-treated rats being 3 to 7 fold greater than the values
from rats treated with normal sheep IgG. When frozen sections of lung from
each of the two groups (anti-GBM versus normal sheep IgG) were stained for
presence of sheep IgG, no fixation was found in rats infused with normal sheep
IgG (Figure 2A). However, the expected pattern of linear vascular deposition of
sheep IgG was observed in lung from rats infused with anti-GBM (Figure 2B).
406 Mulligan et al.
Fig. 1. Effects of anti-GBM infusion on lung vascular permeability (A), alveolar hemorrhage (B),
and neutrophil accumulation (C). Negative controls received 10 mg sheep IgG from preimmune
serum. Positive controls received 10 mg sheep IgG anti-GBM. For each group, N = 4. *P < 0.01
compared to negative control group.
The morphological features of the reactions produced by intravenous infusion
of anti-GBM in the lung are shown in Figure 3. Anti-GBM caused diffuse intra-
alveolar hemorrhage along with accumulation of neutrophils, which were largely
present within venules and interstitial capillaries, although some were found in
intra-alveolar locations. The infusion of 10 mg sheep IgG anti-rat GBM has also
been shown to induce nephrotoxic nephritis with marked proteinuria within 24
h (12).
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Fig. 2. Fluorescence immunostaining of rat lungs for sheep IgG 4 h after infusion of 10 mg IgG
normal sheep IgG (A) or sheep IgG anti-GBM (B). No staining was found with after infusion of
normal sheep IgG whereas, in animals infused with anti-GBM, diffuse vascular (venular) staining
for sheep IgG was present (x 120).
Fig. 3. Morphological features of lung from rats infused intravenously with 10 mg anti-GBM.
Extensive intra-alveolar hemorrhage (open arrow) and fibrin deposition (closed arrow) was con-
sistently observed. Neutrophils were present within interstitial capillaries, as well as some within
alveoli (arrowheads). (Toluidine blue, x 140.)
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Fig. 4. Effects of complement blockade (sCRl) and neutrophil (PMN) depletion on anti-GBM-
induced increases in lung vascular permeability (A) and neutrophil accumulation (B). For each group,
N = 4-6. *P < 0.01 compared to positive control group.
Requirements for Neutrophils and Complement for Lung Injury. Lung
injury induced by anti-GBM infusion was found to be dependent upon com-
plement, since treatment of rats with the complement-blocking reagent, sCRl,
resulted in an 85% decrease in lung vascular permeability (Figure 4A). Similarly,
depletion of blood neutrophils with antibody reduced anti-GBM-induced lung
permeability by 62%. Consistent with reductions in lung permeability, both com-
plement blockade (sCRl) and neutrophil depletion dramatically reduced anti-
GBM-induced lung neutrophil accumulation as measured by MPO content (Fig-
ure 4B). Treatment with sCRl reduced lung MPO values by 79%, while neu-
trophil depletion decreased MPO values by >95%, to nearly undetectable levels.
Thus, it appears that both complement and neutrophils are required for lung
injury induced by anti-GBM.
Cytokine Requirements for Lung Injury. Other models of lung injury have
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Fig. 5. Effects of TNFa and IL-1 blockade on anti-GBM-induced increases in lung vascular per-
meability (A) and neutrophil accumulation (B). For each group, N = 4. *P < 0.01 compared to
positive control group.
shown that the early response cytokines, TNFa and IL-1, are central to the lung
inflammatory response (22, 24). To determine whether these cytokines partici-
pate in lung injury induced by anti-GBM antibody, rats were treated with anti-
TNFa antibody or IL-lRa. Increases in lung vascular permeability induced by
anti-GBM were reduced by anti-TNFa and IL-lRa by 76% and 64%, respec-
tively (Figure 5A). Anti-TNFa and IL-lRa had similar effects on anti-GBM-
induced neutrophil recruitment into lung as measured by tissue MPO content;
anti-TNFa and IL-lRa reduced lung MPO values by 60% and 39%, respectively
(Figure 5B). These data suggest that full development of lung injury after infu-
sion of anti-GBM is dependent upon both TNFa and IL-1.
Requirements for Leukocyte Adhesion Molecules for Lung Injury. Exper-
iments employing blocking antibodies to leukocyte adhesion molecules demon-
Fig. 6. Effects of leukocyte adhesion molecule blockade on anti-GBM-induced increases in lung
vascular permeability (A) and neutrophil accumulation (B). For each group, N = 4-6. *P < 0.01
compared to positive control group.
strated requirements for B1 and B2 integrins and L-selectin for the full induc-
tion of lung vascular permeability (Figure 6A). Treatment with antibody to the
(31 integrin VLA-4 (CD49d) resulted in a 37% reduction in anti-GBM-induced
lung permeability. Similarly, antibodies to the /32 integrins LFA-1 (CD 11 a),
Mac-1 (CDllb) and the B2 common chain (CD18) decreased permeability values
by 59%, 51%, and 78%, respectively. Antibody to rat L-selectin reduced anti-
GBM-induced lung permeability by 51%. Correlating with lung permeability
studies, blockade of leukocyte adhesion molecules decreased neutrophil recruit-
ment into lung (Figure 6B). Blockade of the |31 integrin VLA-4 caused a 30%
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Fig. 7. Effects of endothelial cell adhesion molecule blockade on anti-GBM-induced increases in
lung vascular permeability (A) and neutrophil accumulation (B). For each group, N = 4. *P < 0.01
compared to positive control group.
decrease in lung MPO; blockade of the B2 integrins LFA-1, Mac-1 and the B2
common chain (CD18) reduced lung MPO by 44%, 47%, and 73%, respectively.
Antibody to rat L-selectin produced a 48% reduction in lung MPO content.
Thus, VLA-4, LFA-1, Mac-1 and L-selectin all appear to be required for the
full expression of lung injury after infusion of anti-GBM.
Requirements for Endothelial Adhesion Molecules for Lung Injury. In other
models of lung inflammatory injury, expression of E-selectin and ICAM-1 on the
pulmonary endothelium is essential for full induction of tissue injury, this expres-
sion being induced by TNFa and IL-1 (19,25). To assess the roles of E-selectin and
ICAM-1 during anti-GBM-induced lung injury, rats were treated with blocking
antibodies to these adhesion molecules. Antibodies to E-selectin and ICAM-1 were
both effective in attenuating anti-GBM-induced vascular permeability, reducing
index values by 39% and 74%, respectively (Figure 7A). Consistent with reduc-
tions in lung permeability, anti-E-selectin and anti-ICAM-1 decreased lung MPO
content by 66% and 70%, respectively (Figure 7B). These data suggest that the
full extent of lung injury after infusion of anti-GBM is dependent upon endothelial
expression of E-selectin and ICAM-1.
DISCUSSION
Infusion of anti-GBM into rats caused acute lung injury, as defined by mor-
phological analysis and by measurement of increased vascular permeability and
tissue accumulation of neutrophils. Furthermore, fixation of anti-GBM to the
pulmonary vascular basement membrane results in neutrophil- and complement-
dependent injury that requires B1 and ft integrins and ICAM-1. Additional
requirements for L- and E-selectin in this model of injury are similar to lung
injury induced by IgG immune complexes in which E- and L-selectins are
involved in the recruitment of neutrophils (19, 20). Requirements for TNFa
and IL-1 may reflect the fact that fixation of anti-GBM to the lung vasculature
results in activation of residential interstitial and/or alveolar macrophages. This
activation process could be the result of vascular formation of IgG immune com-
plexes and the presence of complement activation products, causing macrophage
release (perhaps in a VLA-4-dependent manner) of both TNFa and IL-1. In turn,
these cytokines would cause upregulation of endothelial E-selectin and ICAM-1,
thereby promoting adhesive interactions between neutrophils and the pulmonary
vascular endothelium. Following recruitment of neutrophils along chemotac-
tic gradients, vascular injury would presumably then be caused by neutrophil-
derived toxic oxygen products and proteinases.
The cytokine and adhesion molecule requirements for anti-GBM-induced
lung injury are similar in many respects to the requirements in anti-GBM-
induced acute glomerular injury, as defined by proteinuria as well as by mor-
phological changes (12). In the current studies of lung injury, the same amount
of anti-GBM antibody was administered as was given in our previous studies
of anti-GBM-induced glomerular injury (12) in order to facilitate comparison
of cytokine and adhesion molecule requirements between lung and kidney. In
both organs, anti-GBM-induced injury is neutrophil and complement-dependent
(8). However, requirements for leukocyte adhesion molecules differ significantly
in these two in vivo models. While Mac-1 is required for the full develop-
ment of anti-GBM-induced acute glomerular injury, there was no requirement for
LFA-1 in this form of glomerular injury, nor was IL-1 required for development
of glomerular injury (12), which is in contrast to requirements for both Mac-1
and LFA-1 as well as TNFa and IL-1 in anti-GBM-induced lung injury (Fig-
ures 5 and 6). Despite this difference in ft integrin participation, both VLA-4
Cytokine and Adhesion Molecule Requirements in Anti-GBM-induced Lung Injury 413
and L-selectin were required for full development of injury in both lung (Figure
6) and kidney (12).
Additional differences were evident in the requirements for endothelial cell
adhesion molecules. As in the kidney (12), neutrophil accumulation and tis-
sue injury in lung following infusion of anti-GBM requires ICAM-1 (Figure
7). However, E-selectin is not required in the kidney (12), while it is critical to
the development of lung injury (Figure 7). These differences are supported by
immunohistochemical analysis of injured renal tissues. In the kidney, anti-GBM
caused very limited upregulation of glomerular vascular E-selectin. E-selectin
did not play a measurable role in either the accumulation of neutrophils in
glomerular capillaries or in anti-GBM-induced proteinuria. Conversely, ICAM-1
was strongly expressed (as defined by immunostaining) in renal glomeruli fol-
lowing infusion of anti-GBM (12).
In the context of cytokine dependency, there is a distinct difference in
cytokine requirements for anti-GBM-induced lung versus glomerular injury. In
both organs, there is an absolute requirement for TNFa. However, whereas
blocking of IL-1 by IL-1Ra was protective in anti-GBM-induced lung injury
(Figure 5), neither IL-1Ra nor anti-IL-1 was protective in the glomerular injury
model (12). It has also been shown that renal arterial perfusion with TNFa
induces strong expression of ICAM-1 and VCAM-1 in rat glomeruli, whereas
infusion of IL-1 does neither (11). This suggests that the rat glomerulus may be
relatively refractory to the effects of IL-1, at least under the conditions employed.
It has also been suggested that IL-1Ra may reduce proteinuria and neutrophil
accumulation in glomeruli after infusion of anti-GBM (26), however the amount
of IL-1Ra used in those studies was 6-fold in excess of the amount used in our
earlier studies (12). Whether anti-GBM preferentially causes glomerular expres-
sion of TNFa (but not IL-1) is not currently known.
When IgG immune complex-induced dermal vasculitis was induced simul-
taneously with similar induction of alveolitis, distinct differences in cytokine
requirements were also found to be organ specific. In lung, both TNFa and IL-1
were required for neutrophil recruitment and full development of lung injury,
whereas in the dermis IL-1, but not TNFa, was required (27). Immunostaining
of the skin revealed the appearance of IL-1 in mast cells in the absence of TNFa.
Thus while lung macrophages generate both TNFa and IL-1, dermal mast cells
only express IL-1. Differences in organ production of early response cytokines
implies that in human inflammatory conditions in which cytokines are thought
to play a role, such subtle but significant differences may be important in the
design of therapeutic interventions.
Anti-GBM-induced lung injury shares many similarities to requirements
following intrapulmonary deposition of IgG immune complexes (BSA, anti-
BSA). In both models, complement and neutrophils are required (28). However,
only LFA-1 is required for lung neutrophil recruitment induced by IgG immune
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complexes, while Mac-1 engagement involves activation of lung macrophages,
as determined by effects of intravascular or airway instillation of antibodies to
LFA-1 or Mac-1 (29). Anti-GBM-induced lung injury requires the participation
of both LFA-1 and Mac-1 for neutrophil recruitment and full development of
injury, as determined by intravenous administration of anti-LFA-1 or anti-Mac-
1 (Figure 6). In a sense, the anti-GBM model of lung injury, which appears to
be associated largely with intravascular (but little extravascular) accumulation of
neutrophils, is similar to the model of lung injury following intravascular acti-
vation of complement, in which both LFA-1 and Mac-1 are required (27). The
predominant intravascular activation and accumulation of neutrophils in the anti-
GBM model may explain the reason for successful therapy with plasmaphoresis
in patients with Goodpasture's syndrome.
The data presented in this report suggest that the cytokine and adhesion
molecule requirements for anti-GBM-induced lung injury are similar to those
found in other lung injury models. Furthermore, we have identified significant
differences in cytokine and adhesion molecule requirements between anti-GBM
induced lung and glomerular injury. While the reasons for these organ-specific
responses are unclear, these findings may suggest fundamental differences in
pathophysiological mechanisms involved in the development of pulmonary/renal
syndromes and may help to define potential therapeutic interventions.
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